FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3002183655> ?p ?o ?g. }

• W3002183655 endingPage "508" @default.
• W3002183655 startingPage "508" @default.
• W3002183655 abstract "<h3>Importance</h3> Fluid and imaging biomarkers of Alzheimer disease (AD) are often used interchangeably, but some biomarkers may reveal earlier stages of disease. <h3>Objective</h3> To characterize individuals with tau abnormality indicated by cerebrospinal fluid (CSF) assay or positron emission tomography (PET). <h3>Design, Setting, and Participants</h3> Between 2010 and 2019, 322 participants in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) underwent CSF and PET assessments of tau pathology. Data-driven, clinically relevant thresholds for CSF phosphorylated tau (P-tau) (≥26.64 pg/mL) and flortaucipir-PET meta–regions of interest (ROI) (standard uptake value ratio ≥1.37) indicated participants’ tau status as CSF⁻/PET⁻, CSF⁺/PET⁻, CSF⁻/PET⁺, and CSF⁺/PET⁺. Of 1659 ADNI participants with a CSF or flortaucipir assessment, 588 had both measures (1071 were excluded). Among these, 266 were further excluded because they did not have flortaucipir and CSF testing within less than 25 months, leaving 322 for analysis. Of these, 213 were cognitively unimpaired (CU); 98 had mild cognitive impairment (MCI); and 11 had AD dementia. <h3>Main Outcomes and Measures</h3> We compared tau-positive vs tau-negative groups as indicated by either modality or demographic and clinical variables, amyloid β–PET burden, and flortaucipir-PET binding across Braak stage–related ROIs. We also compared 5-year rates of CSF P-tau accumulation and cognitive decline prior to flortaucipir-PET scanning. <h3>Results</h3> Among the 322 study participants, 180 were women (56%), and the mean (SD) age was 73.08 (7.37) years. Two hundred ten participants were CSF⁻/PET⁻(65%); 63 were CSF⁺/PET⁻(19.5%); 15 were CSF⁻/PET⁺(4.6%); and 34 were CSF⁺/PET⁺(10.5%). Most CSF⁻/PET⁺participants had measures near CSF or PET tau thresholds. The CSF⁺/PET⁻participants showed faster 5-year accrual of P-tau and increased flortaucipir-PET binding in early Braak ROIs but similar memory decline compared with CSF⁻/PET⁻participants. Tau-positive individuals by either measure showed increased amyloid β–PET burden. All CSF⁺/PET⁺individuals were amyloid-positive, and 26 had MCI or AD dementia (76%). Compared with the CSF⁻/PET⁻group, CSF⁺/PET⁺individuals had experienced faster 5-year accrual of CSF P-tau and decline in memory and executive function, resulting in reduced cognitive abilities at the time of flortaucipir-PET assessment. <h3>Conclusions and Relevance</h3> Suprathreshold CSF P-tau without flortaucipir-PET abnormality may indicate a stage of AD development characterized by early tau abnormality without measurable loss in cognitive performance. Persons with both tau CSF and PET abnormality appear to have reduced cognitive capacities resulting from faster antecedent cognitive decline. Elevation of CSF P-tau appears to precede flortaucipir-PET positivity in the progression of AD pathogenesis and related cognitive decline." @default.
• W3002183655 created "2020-01-30" @default.
• W3002183655 creator A5014524757 @default.
• W3002183655 creator A5027649726 @default.
• W3002183655 creator A5057796570 @default.
• W3002183655 creator A5082544855 @default.
• W3002183655 creator A5084902960 @default.
• W3002183655 date "2020-04-01" @default.
• W3002183655 modified "2023-10-10" @default.
• W3002183655 title "Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography" @default.
• W3002183655 cites W1964472291 @default.
• W3002183655 cites W1968811469 @default.
• W3002183655 cites W1971647405 @default.
• W3002183655 cites W1993571512 @default.
• W3002183655 cites W2052742260 @default.
• W3002183655 cites W2053116497 @default.
• W3002183655 cites W2069743064 @default.
• W3002183655 cites W2096890121 @default.
• W3002183655 cites W2103861278 @default.
• W3002183655 cites W2111951761 @default.
• W3002183655 cites W2122732330 @default.
• W3002183655 cites W2129771097 @default.
• W3002183655 cites W2145450560 @default.
• W3002183655 cites W2150246483 @default.
• W3002183655 cites W2166536611 @default.
• W3002183655 cites W2171250577 @default.
• W3002183655 cites W2178393107 @default.
• W3002183655 cites W2290598353 @default.
• W3002183655 cites W2302528231 @default.
• W3002183655 cites W2324855862 @default.
• W3002183655 cites W2353776455 @default.
• W3002183655 cites W2426305809 @default.
• W3002183655 cites W2488836793 @default.
• W3002183655 cites W2494586080 @default.
• W3002183655 cites W2625608650 @default.
• W3002183655 cites W2737811824 @default.
• W3002183655 cites W2766125374 @default.
• W3002183655 cites W2781092115 @default.
• W3002183655 cites W2784286559 @default.
• W3002183655 cites W2785757836 @default.
• W3002183655 cites W2792820766 @default.
• W3002183655 cites W2798054687 @default.
• W3002183655 cites W2801498551 @default.
• W3002183655 cites W2808028315 @default.
• W3002183655 cites W2884108666 @default.
• W3002183655 cites W2892024211 @default.
• W3002183655 cites W2892120842 @default.
• W3002183655 cites W2921985330 @default.
• W3002183655 cites W2942151633 @default.
• W3002183655 doi "https://doi.org/10.1001/jamaneurol.2019.4749" @default.
• W3002183655 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6990861" @default.
• W3002183655 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31961372" @default.
• W3002183655 hasPublicationYear "2020" @default.
• W3002183655 type Work @default.
• W3002183655 sameAs 3002183655 @default.
• W3002183655 citedByCount "71" @default.
• W3002183655 countsByYear W30021836552020 @default.
• W3002183655 countsByYear W30021836552021 @default.
• W3002183655 countsByYear W30021836552022 @default.
• W3002183655 countsByYear W30021836552023 @default.
• W3002183655 crossrefType "journal-article" @default.
• W3002183655 hasAuthorship W3002183655A5014524757 @default.
• W3002183655 hasAuthorship W3002183655A5027649726 @default.
• W3002183655 hasAuthorship W3002183655A5057796570 @default.
• W3002183655 hasAuthorship W3002183655A5082544855 @default.
• W3002183655 hasAuthorship W3002183655A5084902960 @default.
• W3002183655 hasBestOaLocation W30021836551 @default.
• W3002183655 hasConcept C118552586 @default.
• W3002183655 hasConcept C126322002 @default.
• W3002183655 hasConcept C142724271 @default.
• W3002183655 hasConcept C143998085 @default.
• W3002183655 hasConcept C15744967 @default.
• W3002183655 hasConcept C185592680 @default.
• W3002183655 hasConcept C199374082 @default.
• W3002183655 hasConcept C2775842073 @default.
• W3002183655 hasConcept C2779134260 @default.
• W3002183655 hasConcept C2779483572 @default.
• W3002183655 hasConcept C2779651940 @default.
• W3002183655 hasConcept C2781197716 @default.
• W3002183655 hasConcept C2984915365 @default.
• W3002183655 hasConcept C2989005 @default.
• W3002183655 hasConcept C502032728 @default.
• W3002183655 hasConcept C55493867 @default.
• W3002183655 hasConcept C58693492 @default.
• W3002183655 hasConcept C71924100 @default.
• W3002183655 hasConceptScore W3002183655C118552586 @default.
• W3002183655 hasConceptScore W3002183655C126322002 @default.
• W3002183655 hasConceptScore W3002183655C142724271 @default.
• W3002183655 hasConceptScore W3002183655C143998085 @default.
• W3002183655 hasConceptScore W3002183655C15744967 @default.
• W3002183655 hasConceptScore W3002183655C185592680 @default.
• W3002183655 hasConceptScore W3002183655C199374082 @default.
• W3002183655 hasConceptScore W3002183655C2775842073 @default.
• W3002183655 hasConceptScore W3002183655C2779134260 @default.
• W3002183655 hasConceptScore W3002183655C2779483572 @default.
• W3002183655 hasConceptScore W3002183655C2779651940 @default.
• W3002183655 hasConceptScore W3002183655C2781197716 @default.
• W3002183655 hasConceptScore W3002183655C2984915365 @default.

• next